Evidence map›Paper›PMID 40088186›Full record

ArticleEpilepsia2025

ENX-101, a GABA

Jordi Serrats, Krishna C Vadodaria, William Brubaker, Melissa Barker-Haliski, H Steve White, Alexis Evrard, Corinne Roucard, Eve Taylor, Kimberly E Vanover, Stephen Cunningham and 2 more

Abstract read
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. ENX-101, a GABAEpilepsia · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jordi SerratsEngrail Therapeutics, San Diego, California, USA.
Krishna C VadodariaEngrail Therapeutics, San Diego, California, USA.ORCID https://orcid.org/0000-0002-3455-0209
William BrubakerEngrail Therapeutics, San Diego, California, USA.
Melissa Barker-HaliskiDepartment of Pharmaceutics, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-8175-0553
H Steve WhiteDepartment of Pharmacy, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washinton, USA.
Alexis EvrardSynapCell S.A.S., Saint-Ismier, France.
Corinne RoucardSynapCell S.A.S., Saint-Ismier, France.
Eve TaylorEngrail Therapeutics, San Diego, California, USA.
Kimberly E VanoverEngrail Therapeutics, San Diego, California, USA.
Stephen CunninghamEngrail Therapeutics, San Diego, California, USA.
Vikram SudarsanEngrail Therapeutics, San Diego, California, USA.
Michael A RogawskiDepartment of Neurology and Pharmacology, School of Medicine, University of California, Davis, Sacramento, California, USA.ORCID https://orcid.org/0000-0002-3296-8193

Funding

Engrail Therapeutics
6 · The paper itself

Abstract

objectiveγ-Aminobutyric acid type A (GABA

methodsENX-101 potentiation of GABA chloride current responses in cells expressing recombinant GABA

resultsENX-101 displayed partial PAM activity with respect to diazepam at GABA SIGNIFICANCE: ENX-101 is an α2,α3,α5-selective GABA

Indexed as

AnticonvulsantsEpilepsyReceptors, GABA-ASeizuresAllosteric RegulationAnimalsDiazepamDisease Models, AnimalDose-Response Relationship, DrugFluorobenzenesHumansKindling, NeurologicMaleMicePatch-Clamp TechniquesRatsAnticonvulsantsDiazepamFluorobenzenesL 838,417Receptors, GABA-ATriazolesantiseizure medicationfocal seizuresGABAA receptor PAMgeneralized seizurespreclinical seizure modelssubtype‐selective

Identifiers

PMID40088186
PMCPMC12169410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.